SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. – United Therapeutics Corporation announced that it will host a webcast to review data from the successful TETON-2 pivotal study evaluating the use of… Read More
Genome BC has announced funding for four new UBC research projects associated with Canada’s Immuno-Engineering and Biomanufacturing Hub (CIEBH), a UBC-led national initiative aimed at accelerating the development of lifesaving… Read More
KELOWNA, BC – Lexaria Bioscience Corp. (the “Company” or “Lexaria“), a global innovator in drug delivery platforms, is pleased to announce successful results from its fluorescently tagged semaglutide (“FTS“) rodent biodistribution… Read More
Pending the European Commission’s final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK… Read More
Idorsia receives approval from Swissmedic for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension. JERAYGO is a new oral antihypertensive therapy –… Read More
